论文部分内容阅读
目的:探讨卵巢恶性肿瘤患者术后化疗期监测CA_(125)、CA_(19-9)、CA_(27-29)及铁蛋白(Fer)的价值.方法:对55例卵巢恶性肿瘤患者在第一年的6周期化疗前、后分别进行血清标志物检测.结果:在晚期卵巢恶性肿瘤患者及化疗期复发者,CA_(125)及CA_(27-29)在6周期化疗后仍继续上升;而早期卵巢恶性肿瘤患者及化疗期无复发者这两种标记物在6周期化疗后下降.结论:在卵巢恶性肿瘤患者手术后对预后的估计及化疗期间的随访中CA_(125)和CA_(27-29)较CA_(19-9)和Fer起着更为重要的作用.
Objective: To investigate the value of monitoring CA 125, CA 19-9, CA 27-29 and Fer Fer during the postoperative chemotherapy in patients with ovarian cancer.Methods: Fifty-five patients with ovarian cancer were enrolled in the Serum biomarkers were tested before and after one year of 6 cycles chemotherapy.Results: CA 125 and CA 27-29 continued to increase after 6 cycles of chemotherapy in patients with advanced ovarian cancer and recurrence during chemotherapy, However, these two markers in patients with early ovarian cancer and without recurrence during chemotherapy decreased after 6 cycles of chemotherapy.Conclusion: The prognosis of patients with ovarian cancer after surgery and the follow-up of chemotherapy during CA 125 and CA - 27-29) play a more important role than CA_ (19-9) and Fer.